Mutations in the omicron variant of the SARS-CoV-2 virus may impact certain molecular tests for COVID-19, the Food and Drug Administration announced yesterday. Specifically, FDA expects a Tide Laboratories test to produce false negative results for the omicron variant and is working with the manufacturer to address the issue. The agency said it does not believe the test is used for high-volume testing, and lists laboratories that perform the test. FDA also identifies certain tests that are less sensitive to a mutation in the omicron variant, but said it does not expect the variant to impact the overall sensitivity of those tests. The update includes recommendations for clinical laboratory staff and health care providers using these tests. 

Related News Articles

Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
The Senate Health, Education, Labor and Pensions Committee today 17-3 to pass as amended the Pandemic and All-Hazards Preparedness and Response Act (S. 2333),…
Headline
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for…
Headline
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years…
Headline
The Food and Drug Administration authorized for marketing the first at-home over-the-counter test for COVID-19 using a traditional premarket review…
Headline
The Centers for Medicare & Medicaid Services May 31 released regulatory changes to the COVID-19 health care staff vaccination requirements and long-term…